Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 10/20 | 0.40 |
| ▸ | RAF1 | P04049 | 7/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113952 | 0.89 | MTOR (0.42) | DGAT1ADORA2AADORA1BRAFRAF1 | |
| SCHEMBL18113910 | 0.85 | BRAF (0.45) | BRAFRAF1 | |
| SCHEMBL20481591 | 0.85 | ADORA2A (0.42) | WDR5ADORA2AADORA1BRAFRAF1 | |
| SCHEMBL18113848 | 0.85 | ADORA2A (0.39) | DGAT1ADORA2AADORA1BRAFRAF1 | |
| SCHEMBL18113822 | 0.85 | ADORA2A (0.42) | ADORA2AADORA1BRAFRAF1KCNQ3 | |
| SCHEMBL18113832 | 0.84 | ALDH1A1 (0.47) | — | |
| SCHEMBL18113889 | 0.83 | ABL1 (0.37) | POLQ | |
| SCHEMBL18113948 | 0.83 | POLQ (0.36) | POLQ | |
| SCHEMBL18113934 | 0.82 | ADORA2A (0.41) | ADORA2AADORA1BRAFRAF1 | |
| SCHEMBL18113802 | 0.81 | PI4KB (0.35) | POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | claimed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | POLQ 4676/4885DGAT1 1769/4885WDR5 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.